History
Colorectal cancer is a collective term for cancers that arise in the large intestine (colon) and rectum. In the past, it was often discovered only after symptoms such as changes in bowel habits or bleeding became obvious, and it was common for patients to already have advanced disease at the time of diagnosis. The situation changed greatly as endoscopic technology for directly viewing the inside of the colon advanced. As it became possible to find and remove polyps with colonoscopy, the perspective took hold that cancer can not only be "treated" but also prevented at the "stage before it becomes cancer." In other words, colorectal cancer is a cancer for which early detection is important, but at the same time it has become a representative cancer whose very occurrence can be reduced by removing precancerous lesions.
As pathology and molecular biology advanced, it also became clear that colorectal cancer does not arise through a single pathway. In some cases, the stepwise change from normal mucosa through a polyp to cancer is central, while in others, because of a genetic defect, even small lesions tend to become malignant quickly or multiple lesions tend to develop. As it became known that certain hereditary diseases, such as familial polyposis and Lynch syndrome, greatly increase the risk of colorectal cancer, family history and genetic counseling became an important pillar of prevention strategies.
Recent studies emphasize that the response to drugs can differ greatly depending on the genetic changes in the tumor, and the trend has strengthened toward personalizing treatment to include "the nature of the cancer (its molecular features)" rather than deciding it based only on "the location of the cancer." Meanwhile, as increases in colorectal cancer at younger ages have recently been reported in many countries, discussion continues in the direction of lowering the age at which screening begins or seeking out high-risk groups more actively.
Causes
The cause of colorectal cancer is difficult to pin down to a single factor. Lifestyle factors and genetic factors act together and sometimes influence each other. In terms of lifestyle, diet is cited as an important risk factor. A diet with frequent red meat or processed meat, and a diet low in fiber and high in calories, are often observed to increase risk. Obesity, physical inactivity, smoking, and alcohol consumption are also frequently mentioned as factors that increase risk.
Conditions in which chronic inflammation persists in the intestine, such as inflammatory bowel disease, can raise the risk of colorectal cancer. In addition, people who have colon polyps may have a higher future risk of colorectal cancer, and the risk differs depending on the type, size, and number of polyps. However, not all polyps become cancer, and it is important that removing polyps appropriately can reduce the risk of colorectal cancer.
Genetic causes also exist. Hereditary diseases such as Lynch syndrome and familial adenomatous polyposis can cause colorectal cancer to develop at a relatively young age. Therefore, it is neither "safe because there is no family history" nor "certain to occur because there is a family history." To lower risk, it is realistic to plan screening by looking together at an individual's age, family history, past history of polyps, and lifestyle.
Genetic Epidemiology
Genetic epidemiology deals with how the genetic risk of colorectal cancer is distributed in a population and which genetic changes are related to which forms of colorectal cancer. Colorectal cancer is common even in people without a family history, but if a first-degree relative (parent, sibling, child) has colorectal cancer, the risk can increase. In particular, if two or more family members have been diagnosed with colorectal cancer, or if there is a family history of diagnosis at a young age, genetic factors are suspected more actively.
One of the representative hereditary diseases is Lynch syndrome. In this case, a genetic problem in DNA repair function means that cells cannot properly correct accumulating genetic errors, and the risk of cancer increases. In another disease, familial adenomatous polyposis, a very large number of polyps develop in the colon, and if untreated, the likelihood of progression to cancer is very high. These diseases account for only a portion of all colorectal cancers, but once diagnosed, the prevention strategy changes not only for the patient but for the whole family.
Recent studies are expanding the approach of understanding colorectal cancer by dividing it according to molecular features. In certain tumors, genetic instability is prominent, and this difference can be an important clue to prognosis and treatment response, especially to whether immunotherapy will be effective. However, genetic information has greater meaning when it is integrated with stage, tumor location, histological findings, and the patient's condition rather than used alone to reach a conclusion.
General Epidemiology
Colorectal cancer is one of the most common cancers worldwide, and its incidence differs greatly by country and region. In general, it has been reported to tend to be more common in regions with a high economic level where westernized lifestyles are widespread. It is also a cancer whose risk increases with age. However, as reports have recently continued that colorectal cancer is increasing in relatively young adults under 50, the existing perception that "colorectal cancer occurs mainly in older people" is being partly revised.
Colorectal cancer groups together colon cancer and rectal cancer, but the two cancers can differ in treatment strategy. Because rectal cancer is located in the pelvis, the extent of surgery and the role of radiation therapy often become important, whereas for colon cancer, surgery and chemotherapy are often the center of treatment. It is also known that symptom patterns, genetic features, and patterns of metastasis can differ by site of origin (right colon, left colon, rectum).
The most important factor determining prognosis is the stage at diagnosis. Screening is important not only because it finds cancer earlier but also because removing polyps can reduce the occurrence of cancer itself. Recent studies emphasize that increasing access to screening and improving the quality of testing are key elements in lowering colorectal cancer mortality.
Pathogenesis
Colorectal cancer can be understood as a process in which epithelial cells of the colonic and rectal mucosa change into cancer cells through multiple stages of change. In many cases, colon polyps serve as the precancerous stage, and over time genetic changes in the cells accumulate and progress to cancer. Not all polyps have the same nature. Some polyps carry a relatively low risk, while others are more likely to progress to cancer. That is why the histological type, size, and number of polyps and the degree of cellular abnormality determine the follow-up management plan.
At the molecular level, at least several major pathways are discussed. In the pathway centered on chromosomal instability, changes in which tumor suppressor gene function weakens or cell growth signals are excessively switched on can accumulate step by step. In another pathway, cancer can arise as small errors accumulate repeatedly because of abnormal DNA repair function. In some tumors, a characteristic is observed in which the cancer progresses as the way gene expression is regulated in specific regions (epigenetic changes) changes greatly.
Recent studies emphasize that the gut microbiota, chronic inflammation, immune responses, and metabolic state affect the tumor microenvironment and can influence cancer growth, metastasis, and treatment response. To explain why, even at the same stage, some patients have no recurrence and others do, the trend of looking not only at the tumor cells themselves but also at the surrounding environment is spreading.
Symptoms
Colorectal cancer often has no symptoms in its early stages. For this reason, it is sometimes found incidentally on screening or on tests performed for other reasons. When symptoms develop, their pattern differs depending on the location and extent of the cancer. Commonly mentioned symptoms are blood in the stool (bright red or dark red) and changes in bowel habits. Constipation and diarrhea may alternate, or a change in which stools become thinner than usual may persist.
Abdominal pain, a feeling of abdominal bloating, frequent gas, and a feeling of incomplete evacuation (a feeling that stool remains even after a bowel movement) may also appear. If the cancer causes bleeding, anemia can develop, and as a result fatigue, dizziness, and shortness of breath can appear. Loss of appetite and unexplained weight loss may accompany relatively advanced cases.
In cancers close to the rectum, symptoms such as anal bleeding, pain during bowel movements, and mucus in the stool can be more prominent. Conversely, cancer in the right colon sometimes first appears as chronic anemia rather than as visible bleeding. If it progresses to the point of blocking the bowel, symptoms of bowel obstruction—abdominal pain, vomiting, and no passage of stool or gas at all—can appear, which can become an emergency.
Signs
Signs are findings confirmed objectively on examination or testing. On physical examination, an abdominal mass may be felt, or a lump may be felt on digital rectal examination. However, in many patients it is difficult to find a clear abnormality by examination alone. On blood tests, iron deficiency anemia can be an important clue. In particular, unexplained iron deficiency anemia in men or postmenopausal women requires evaluation considering the possibility of colonic bleeding.
The fecal occult blood test detects small amounts of bleeding that cannot be seen and is widely used as a screening tool. If it is positive, the cause must be confirmed by colonoscopy. On colonoscopy, polyps, cancerous lesions, and mucosal ulcers or bleeding points can be seen directly.
Imaging confirms the extent of the tumor and whether there is metastasis. Computed tomography can be used to check for liver metastasis, lung metastasis, and lymph node metastasis, and in rectal cancer, pelvic magnetic resonance imaging plays an important role in evaluating the extent of local invasion. Blood tumor markers (e.g., carcinoembryonic antigen) are often used as an adjunct in follow-up and surveillance for recurrence after treatment rather than for diagnosis.
Screening
Colorectal cancer screening has two purposes. The first is to find cancer early and improve treatment outcomes, and the second is to reduce the occurrence of cancer by removing polyps. In the average-risk group, it is recommended to begin screening from a certain age. As recent studies have reported an increase in colorectal cancer at younger ages, several guidelines have discussed lowering the age at which screening begins.
Screening methods can be broadly divided into stool-based tests and endoscopy-based tests. Fecal occult blood tests and stool-based molecular tests are relatively simple and accessible, but if the result is positive, it must be confirmed by colonoscopy. Colonoscopy allows observation of the entire colon and removal of polyps, so its preventive effect is large, but the preparation process is cumbersome, the test itself is burdensome, and there is a rare risk of complications. In addition, virtual colonoscopy using CT of the colon is sometimes used, and in this case too, an actual endoscopy is needed if abnormal findings are present.
High-risk groups need a separate strategy. In people with a first-degree family history, a past history of high-risk polyps, inflammatory bowel disease, or a hereditary syndrome, starting at an earlier age or performing endoscopy at shorter intervals is considered. The most important thing in screening is closer to "choosing a test one can keep undergoing and having it at the set intervals" than to "which test is best."
Diagnosis
When colorectal cancer is suspected or an abnormality is found on screening, a process of taking tissue from the lesion and examining it under a microscope is needed for a definitive diagnosis. The most standard method is colonoscopy. The lesion is viewed directly through the endoscope, and a biopsy is performed to confirm whether it is cancer. If the lesion is in the rectum, proctoscopy or digital rectal examination can also be helpful.
After confirmation, the stage is evaluated. For colorectal cancer, how deeply it has invaded the bowel wall, whether it has spread to nearby lymph nodes, and whether it has metastasized to other organs such as the liver or lungs determine the treatment plan. For this, CT of the abdomen and chest is commonly used. Because the relationship with structures in the pelvis is important in rectal cancer, pelvic magnetic resonance imaging or endoscopic ultrasound may be used.
Recent studies show that the area in which the results of molecular testing and immune-related testing of tumor tissue greatly affect treatment selection is expanding. In metastatic disease in particular, the choice of targeted therapy can differ depending on genetic changes, and there are subtypes that respond well to immunotherapy. Therefore, in metastatic disease, tissue testing and molecular testing serve as the compass for treatment.
Treatment
Treatment of colorectal cancer differs depending on the stage, location (whether it is colon cancer or rectal cancer), and the patient's condition. In early colon cancer, the center of treatment is surgical resection of the part of the bowel containing the tumor along with nearby lymph nodes. If the pathology results show a high risk of recurrence or confirm lymph node metastasis, adjuvant chemotherapy after surgery may be recommended.
Because of its anatomical location, the risk of local recurrence can be more of a problem in rectal cancer, so strategies combining radiation therapy and chemotherapy before or after surgery are often used. When the tumor is located close to the anus, a surgical plan that considers bowel function and quality of life is needed, and in some cases a stoma may be required. In metastatic colorectal cancer, the goal of treatment can range between "cure" and "disease control." With metastasis limited to the liver or lungs, there are also situations in which a cure is pursued with surgery or local treatment.
Recent studies report that immunotherapy can be highly effective in tumors with certain molecular features, and some targeted therapies are meaningful only when certain genetic changes are present. Therefore, in metastatic disease, tissue testing and molecular testing serve as the compass for treatment, and the direction of personalizing treatment to "the nature of the cancer" is being strengthened.
Prognosis
The prognosis of colorectal cancer depends most strongly on the stage at diagnosis. If it is found at an early stage confined to the bowel, the likelihood of cure with surgery is high. If there is lymph node metastasis, the risk of recurrence increases, but adjuvant chemotherapy after surgery can reduce that risk. If it has metastasized to other organs, the prognosis worsens, but because treatment is advancing rapidly, the group of patients who can expect long-term survival is also growing.
When discussing prognosis, recurrence, complications, and functional outcomes must be considered together with survival rates. After surgery, changes in bowel habits, stoma care, functional problems due to nerve damage, and aftereffects of radiation therapy can affect quality of life. In rectal cancer, changes in bowel, sexual, and urinary function are treated as important.
Recent studies are strengthening the view that colorectal cancer is not a single disease but a collection of several subtypes. Recurrence risk and treatment response can differ depending on molecular features, the immune microenvironment, and tumor location, and approaches that personalize treatment to reflect this are expanding. After treatment, imaging, blood tests, and endoscopic follow-up are carried out in a planned manner for a certain period to detect recurrence early.
Prevention
Prevention of colorectal cancer can be divided into two pillars: "screening" and "lifestyle improvement." Screening is particularly effective in preventing colorectal cancer, because finding and removing polyps eliminates the chance for them to progress to cancer. Therefore, regular testing at the recommended age and according to risk level is the most direct method of prevention. If there is a family history or a high-risk condition, an earlier start and closer follow-up may be needed.
In terms of lifestyle, maintaining a healthy weight, regular physical activity, quitting smoking, and moderating alcohol consumption are fundamental. A diet with sufficient fiber, such as vegetables, fruits, and whole grains, can be helpful, and reducing intake of processed meat and red meat is observed to lower risk. Recent studies discuss that interactions between the gut microbiota and dietary habits may affect cancer risk, but we are not yet at a stage where any single food can guarantee prevention.
Drug prevention (e.g., aspirin) is discussed in some situations, but because side effects such as bleeding must be weighed against the benefits, it is difficult to apply it uniformly to the general public. Ultimately, the most reliable strategy for preventing colorectal cancer is not to miss screening tailored to individual risk and to maintain lifestyle habits that are sustainable over the long term.